GSK says EMA validates cancer drug submission
GSK
1,536.00p
16:55 20/09/24
-2.45%
-38.50p
GSK said the European Medicines Agency had validated the its submission for a potential new indication of its treatment for a type of gynaecological cancer known as mismatch repair deficient primary advanced or recurrent endometrial cancer.
FTSE 100
8,229.99
17:14 20/09/24
n/a
n/a
FTSE 350
4,543.89
16:49 20/09/24
n/a
n/a
FTSE All-Share
4,501.08
17:04 20/09/24
n/a
n/a
Pharmaceuticals & Biotechnology
22,415.97
16:49 20/09/24
-1.31%
-296.71
The move comes after the first part of a phase 3 trial of its Jemperli (dostarlimab) treatment in combination with chemotherapy for adult patients.
As a result, the EMA's Committee for Medicinal Products for Human Use will begin the formal review process to make a recommendation to the European Commission regarding marketing authorisation for the potential new indication.
Reporting by Frank Prenesti for Sharecast.com